“Lymphoproliferative Skin Lesion As a Previously Unreported Adverse Event Detected in a Patient Receiving MSTR TB Treatment”. Journal of Pharmacovigilance and Drug Research 3, no. 2 (June 1, 2022): 34–37. Accessed November 12, 2026. http://jpadr.com/index.php/jpadr/article/view/62.